the daily requirement of B12 is around 2.5 mcg per day
This comparison focuses on four compounds that define the current state of the field: semaglutide (the established benchmark), tirzepatide (the dual-agonist leader), retatrutide (the triple-agonist frontier), and orforglipron (the oral non-peptide breakthrough)
Wegovy (semaglutide) at the standard 2.4 mg dose produces about 14.9% weight loss over 68 weeks, and even the newer high-dose 7.2 mg formulation reaches approximately 20.7% over 72 weeks
Oral changes, when they occur, are usually indirect and manageable with hydration, nutrition, and routine care
You feel fuller longer, blood sugar stays more stable, and in many cases, cravings start to calm down